

Hospitalization Risk in HIV-COVID19

1

2 **Increasing Numbers of Non-communicable Disease Co-morbidities: Major Risk**

3 **Factors for Hospitalization among a Cohort of People with HIV and COVID-19**

4 **Coinfection**

5

6 Michael D. Virata,^{a*} Sheela V. Shenoi,^a Joseph Ladines-Lim,^b Merceditas S. Villanueva,^a and

7 Lydia A. Barakat^a

8

9 ^aYale School of Medicine, Internal Medicine, Section of Infectious Diseases, New Haven,

10 Connecticut

11 ^bUniversity of Michigan, Internal Medicine and Pediatrics, Ann Arbor, Michigan

12

13 *Corresponding author: michael.virata@yale.edu

14

15

Hospitalization Risk in HIV-COVID19

16 All authors contributed significantly to the study design and to the collection, organization,
17 and analysis of the data, and participated in the preparation of this report. The authors
18 have approved the final version for submission.

19

Hospitalization Risk in HIV-COVID19

20 **Abstract**

21 Data regarding coronavirus disease (COVID-19) infection complications among people with
22 HIV (PWH) are expanding but sometimes conflicting. This report presents the results of a
23 retrospective review of 103 patients at a single urban academic health center with
24 confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The
25 study showed that hospitalization is related to host factors such as age 65 years or older with
26 an increasing number of specific non-communicable disease comorbidities, and not to HIV-
27 attributable factors.

28

29

30

Hospitalization Risk in HIV-COVID19

31 **Introduction**

32 The first laboratory-confirmed case of coronavirus disease (COVID-19) secondary to severe
33 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States (US)
34 came to the attention of the Centers for Disease Control and Prevention (CDC) on
35 January 21, 2020. A mere 12 months later, cases had reached 24.5 million, with over 500,000
36 deaths recorded.[1]

37 Initial reports from Wuhan, China, identified a number of risk factors for severe COVID-19
38 and mortality. Among these factors were older age, male gender, and co-morbidities such as
39 hypertension, diabetes, chronic cardiovascular and respiratory disease, and
40 immunosuppressed conditions.[2] At that time, it was not known whether clinically stable
41 persons with HIV (PWH) who were diagnosed with COVID-19 would be more likely to be
42 hospitalized or to develop severe illness.

43 Several very early case series showed that clinical outcomes among PWH were not any worse
44 than those for patients without HIV,[2,3,4] and found no excess risk of morbidity and
45 mortality in symptomatic SARS-CoV-2 co-infected patients with fully suppressed HIV,
46 compared with HIV-uninfected patients.[5,6] Similarly, a US study matched 21 HIV-infected
47 against 42 HIV-uninfected patients, all hospitalized for COVID-19, and noted no significant
48 difference in clinical course or outcomes.[7] A few months into the pandemic, there was more
49 evidence from several areas in the US that HIV was not being identified as a risk factor for
50 hospitalization.[8] However, a recent systematic review of 25 published studies of PWH co-

Hospitalization Risk in HIV-COVID19

51 infected with SARS-CoV-2 demonstrated that among 252 patients, 65% were hospitalized and
52 17% required admission to an intensive care unit (ICU).[9]

53 To gain a better understanding of the risk factors for hospitalization among PWH infected
54 with SARS-CoV-2, a cohort study comparing ambulatory and hospitalized co-infected patients
55 at a single urban academic center was made during the first year of the pandemic.

56 **Methods Used in the Study**

57 *Study Design and Population*

58 The study involved a retrospective chart review of PWH 18 years old or over who had a
59 laboratory-confirmed SARS-CoV-2 infection between January 21, 2020, and January 20, 2021,
60 using reverse transcription polymerase chain reaction (RT-PCR) test results. All patients
61 received their primary care at two HIV ambulatory clinics within the Yale–New Haven Hospital
62 (YNHH) academic medical center in New Haven, Connecticut. Eligible patients were divided
63 into hospitalized and ambulatory groups.

64 *Data Sources and Analysis*

65 A standardized form was used in abstracting data from electronic medical records (Epic
66 Systems Corporation) including demographic information, co-morbidities, and clinical
67 parameters such as body mass index (BMI), as well as HIV-specific information including AIDS
68 diagnosis, antiretroviral therapy (ART), CD4 cell count and HIV viral load (HIVVL) before
69 admission. Among the COVID-specific information items were COVID-19-related symptoms,
70 reverse transcription polymerase chain reaction (RT-PCR) test results, and COVID-19

Hospitalization Risk in HIV-COVID19

71 management protocols including specific SARS-CoV-2 therapies. Predetermined clinical
72 outcomes included the need to escalate to ICU level of care, and all-cause mortality. HIVVL
73 suppression was defined as <200 copies per milliliter (copies/ml) of blood; history of AIDS, as
74 having had an opportunistic infection or a CD4 count of <200 cells/mm³ or both; and obesity,
75 as BMI>30.

76 Continuous and categorical variables were summarized as medians or means, and
77 percentages as appropriate, and bivariate analysis comparing hospitalized with
78 nonhospitalized patients using SPSS Version 26.0 was performed to identify factors that
79 differentiated between the two groups. Differences with a *p*-value less than 0.05 were
80 significant. Multivariable backward logistic regression identified independent correlates for
81 hospitalization.

82 The study was approved by the Yale University Institutional Review Board and the
83 requirement for an informed consent was waived for this retrospective review. All patient
84 records and pertinent information were de-identified prior to the analysis.

85 **Results**

86 *Demographics*

87 Among 1,469 PWH receiving care at the two clinics, 103 (7%) had confirmed COVID-19. The
88 median age was 56 (interquartile range [IQR] 45–62) years—72 PWH (69.9%) were >50 years
89 old, while 17.5% were >65 years old—and 46.6% were women, 43.7% were African
90 Americans, and 16.5% were Latinx (**Table 1**). The median CD4 count was 735 cells/mm³ (IQR

Hospitalization Risk in HIV-COVID19

91 434–928), 98.1% of the patients were prescribed ART, and 92.2% had HIVVL suppression.
 92 Among the 88% with co-morbidities, 51.5% had hypertension; 43.7%, obesity; 34%,
 93 underlying chronic lung disease; 27.2%, cardiovascular disease; 27.2%, diabetes mellitus; and
 94 22.3%, chronic kidney disease. While 56.3% of PWH were former smokers, active use of
 95 tobacco was documented in 22.3%, alcohol in 27.2%, and illicit substances in 13.6%.

Table 1. Demographics and Clinical Characteristics of PWH with SARS-CoV-2, 1/21/2020-1/20/2021 (n=103)

	Total (n=103)	Ambulatory (n=69)	Hospitalized (n=34)	p-value	OR (95% CI)	
Demographics						
Median age (IQR)	56 (45–62)	55 (42.5–59)	58 (52.3–67.3)	0.40 [#]		
Age>50 yrs, n (%)	72 (69.9)	45 (65.2)	27 (79.4)	0.14		
Age>65 yrs, n (%)	18 (17.5)	8 (11.6)	10 (29.4)	0.025	3.18 (1.12–9.01)	
Women, n (%)	48 (46.6)	32 (46.4)	16 (47.1)	0.95		
African Americans, n (%)	45 (43.7)	30 (43.5)	15 (44.1)	0.95		
Latinx, n (%)	17 (16.5)	13 (18.8)	4 (11.8)	0.27		
HIV History						
Median years living with HIV (IQR)	16.5 (9–23.8)	17 (8–25)	16 (10–23)	0.83 [#]		
History of AIDS, n (%)	46 (44.7)	30 (43.5)	16 (47.1)	0.75		
History of CD4<200 cells/mm ³ , n (%)	43 (41.8)	28 (40.5)	15 (44.1)	0.77		
History of OI, n (%)	24 (23.3)	18 (26.1)	6 (17.6)	0.25		
On ART, n (%)	101 (98.1)	67 (97.1)	34 (100)	0.32		
Median CD4 count (IQR)	735 (434–928)	718 (397–931)	784 (466–924)	0.67 [#]		
Proportion VL suppressed (VL<200), n (%)	95 (92.2)	65 (95.2)	30 (88.2)	0.25		
Co-morbidities						
Active smoking, n (%)	23 (22.3)	15 (21.7)	8 (23.5)	0.84		
Former smoking, n (%)	58 (56.3)	37 (53.6)	21 (61.8)	0.43		
Active substance use, n (%)	14 (13.6)	6 (8.7)	8 (23.5)	0.039	3.2 (1.0–10.2)	
Active alcohol use, n (%)	28 (27.2)	19 (27.5)	9 (26.5)	0.91		
Diabetes mellitus, n (%)	28 (27.2)	14 (20.3)	14 (41.2)	0.025	2.75 (1.1–6.8)	
Median HgbA1C (IQR) (n=50)	7.8 (6.4–8.5)	7.1 (6.2–8.3)	8.3 (6.6–9.0)	0.20 [#]		
Chronic lung disease, n (%)	35 (34)	18 (26.1)	17 (50)	0.016	2.83 (1.20–6.7)	3.35 (1.28–8.72)
Chronic kidney disease, n (%)	23 (22.3)	10 (14.5)	13 (38.2)	0.007	3.65 (1.39–9.57)	
Cardiovascular disease, n (%)	28 (27.2)	13 (18.8)	15 (44.1)	0.007	3.4 (1.37–8.42)	3.4 (1.27–9.12)
Hypertension, n (%)	53 (51.5)	31 (44.9)	22 (64.7)	0.059	2.25 (0.96–5.25)	
Hepatitis C, n (%)	23 (22.3)	11 (15.9)	12 (35.3)	0.027	2.88 (1.1–7.47)	
Median BMI (IQR)	28.9 (25.2–34.9)	29.3 (25.7–35.0)	26.8 (24.7–36.0)	0.30 [#]		
Obesity (BMI>30), n (%)	45 (43.7)	32 (46.4)	13 (38.2)	0.43		
Any co-morbidity, n (%)	93 (90.3)	62 (89.9)	31 (91.2)	0.83		
Number of co-morbidities	3 (1–4)	2 (1–3)	4 (2–5)	0.001*	1.61 (1.22–2.13)	

96 *Logistic regression; #Mann Whitney U; PWH-persons with HIV

97

98

Hospitalization Risk in HIV-COVID19

99 *Characterization of Hospitalized PWH*

100 Thirty-four PWH (33.0%) were hospitalized and 69 (67.0%) were ambulatory. Hospitalized
101 PWH represented <1% of all COVID-19-related admissions to YNHH during the study period.
102 In the bivariate analysis, age and multiple co-morbidities were significant. In the adjusted
103 analysis (**Table 1**), on the other hand, those who were hospitalized were more likely to be at
104 least 65 years old (odds ratio [OR] 3.11, 95% confidence interval [CI] 0.97–9.98) and to have
105 chronic lung disease (OR 3.35, 95% CI 1.28–8.72) or cardiovascular disease (OR 3.4, 95% CI
106 1.27–9.12). Moreover, incremental numbers of co-morbidities were associated with
107 hospitalization (OR 1.61, 95% CI 1.22–2.13). AIDS history and last CD4 count were not
108 associated with hospitalization. There was no significant difference in ART coverage or HIVVL
109 suppression between inpatients and outpatients.

110 Among those who were hospitalized (**Table 2**), the most frequently prescribed inpatient
111 therapies for COVID-19 were hydroxychloroquine (47.1%), tocilizumab (23.5%), and
112 remdesivir and steroids (14.7%). A small proportion (14.7%) received lopinavir/ritonavir or
113 atazanavir. During hospitalization, five patients (14.7%) required escalation to ICU level of
114 care, six patients (17.6%) needed intermediate (step-down) care; and four (11.8%) had to be
115 placed on mechanical ventilation. The median length of stay was nine days (IQR 3–15). Only
116 one patient (2.9%) died within 30 days of hospital admission. In a subset of hospitalized
117 patients (n=15), repeat CD4 counts revealed a decreased median of 417.8 (IQR 186–617)

Hospitalization Risk in HIV-COVID19

118 cells/mm³. Repeat HIVVL testing done for 59% of patients showed full viral suppression in
 119 95% of that subset (**Table 2**).

Table 2. Characteristics of Hospitalized PWH (n=34)	
HIV Clinical Parameters:	
Median CD4 Count cells/mm ³ during hospitalization (n=15)	417.8 (186 – 617)
HIV Viral Suppression during hospitalization (<200 copies/mm ³) (n=20)	19 (95%)
COVID Therapy:	
Hydroxychloroquine	16 (47.1%)
Tocilizumab	8 (23.5%)
Remdesivir	5 (14.7%)
Methylprednisolone	5 (14.7%)
Atazanavir	3 (8.8%)
Lopinavir/Ritonavir	2 (5.9%)
Convalescent Plasma	0 (0%)
No therapy	6 (17.6%)
Clinical Outcomes:	
Length of Stay (days)	9 (3-15)
Escalation of care to critical care unit	11(32.4%)
Stepdown:	6 (17.6%)
ICU:	5 (14.7%)
Mechanical Ventilation	4 (11.8%)
Mortality (of hospitalized/all PWH)	1 (2.94%/0.97%)

120 PWH-persons with HIV

121 **Discussion**

122 This report describes the impact of COVID-19 infection on PWH at a single urban academic
 123 medical center in the US and identifies correlates of hospitalization. The study confirmed that
 124 hospitalization is related to host factors, such as older age and specific as well as multiple
 125 co-morbidities, and not to traditional metrics of HIV disease or immunosuppression. The
 126 median age of the cohort was similar to that in other studies and was lower than that of
 127 hospitalized HIV-uninfected patients with COVID-19.[3,8,10,11,12] The predominant co-

Hospitalization Risk in HIV-COVID19

128 morbidities for hospitalized patients—chronic lung and cardiovascular disease—were similar
129 to those for patients in other COVID-19 cohorts. [8,13,14]

130 PWH are living longer with effective ART use, but are increasingly being diagnosed with new
131 and multiple co-morbidities, particularly among communities of color.[15] While there is
132 growing evidence that HIV-associated immunosuppression is not thought to be associated
133 with COVID-19-related hospitalization or death, indirect measures of HIV and aging, as
134 manifested in co-morbidities, still correlate with COVID-19 hospitalization. More recent
135 reports from Moran et al.[16] from Grady Memorial Hospital in Atlanta, Georgia, found that
136 co-morbidity burden was associated with hospitalization in a dose-dependent fashion when
137 comparing hospitalized and nonhospitalized PWH with COVID-19. Sun et al. [17], in a National
138 COVID Cohort Collaborative (N3C) study, looked at a large database of PWH with COVID-19
139 at US academic medical centers, compared with solid organ transplant patients, again noted
140 that increased hospitalization and mechanical ventilation among PWH was related to the co-
141 morbidity burden and not to specific demographics. However, the odds of hospitalization
142 were observed to be higher for those with HIV than for the HIV-uninfected.

143 Despite well-maintained pre-COVID CD4 counts and suppressed HIVVL, HIV-associated
144 immune dysfunction may affect the person's ability to respond to the exuberant
145 inflammatory reaction, resulting in clinical deterioration from COVID-19 [18]. Yendewa
146 et al.[19] assessed a large health-care network of 44 facilities where PWH under less intensive
147 ART and with much lower rates of viral suppression had higher odds of hospitalization, ICU
148 admission, and mechanical ventilation, than patients without HIV infection. Co-morbidities

Hospitalization Risk in HIV-COVID19

149 were not reported, but the two groups of patients did have comparable 30-day mortality
150 rates. Interestingly, among a subset of our hospitalized patients with CD4 counts performed
151 after admission in this study, there was a significant drop in the absolute CD4 count
152 consistent with nonspecific changes seen in acute illness.

153 The direct antiviral benefit of ART could be another explanation for less severe disease. A
154 lower risk of hospitalization and severe disease was observed among other cohorts of
155 patients on tenofovir disoproxil.[20,21] The current study, though limited by sample size
156 showed no indication that receipt of ART had any effect on the clinical course or outcome.
157 Differences in outcomes such as mortality may also have been affected by the variety of care
158 standards used in each unique facility. Maintaining the current ART of patients as well as
159 current standards of care, produces favorable outcomes for the overwhelming majority.

160 The study had several limitations. First, this was a retrospective review of PWH at a single
161 urban institution, and this group may not be representative of the general global population
162 of PWH. Second, hospitalized cases were identified through a health systems database with
163 laboratory confirmation, leaving open the possibility that other PWH from the YNHH clinics
164 were tested for SARS-CoV-2 or hospitalized elsewhere. Third, although reports show that
165 COVID-19 disproportionately affects disadvantaged populations[22], the PWH cohort in the
166 current study, consisting largely of minorities, and people over 50 years with multiple co-
167 morbid conditions but with ready access to advanced treatments, achieved favorable
168 outcomes overall. Finally, these data reflect the COVID-19 trends among PWH before the

Hospitalization Risk in HIV-COVID19

169 initiation of mass vaccination. As the pandemic continues to evolve and new variants emerge,
170 these circumstances could alter the risk factors for hospitalization and severe disease.

171

172 **Conclusion**

173 In this retrospective study, 103 PWH diagnosed with COVID-19 in an urban, resource rich
174 academic center were identified. Compared with PWH managed as outpatients, those
175 needing hospitalization were found to be older, with significantly more non-communicable
176 co-morbidities. Mortality for the entire group was <1%. HIV-attributable factors were not
177 associated with hospitalization for COVID-19.

178

179 **Acknowledgments**

180 We are we grateful for the editing assistance of Mary-Ann Asico in the preparation of the
181 report. Most importantly, we thank our patients.

182 **Conflicts of Interest**

183 Sheela Shenoi's spouse worked for Merck Pharmaceuticals from 1997 to 2007 and retains
184 company stock in his retirement account. While no conflict of interest is involved, this
185 information is included here in the interest of full disclosure. All other authors report no
186 potential conflicts of interest.

Hospitalization Risk in HIV-COVID19

187 **Financial Disclosures**

188 Sheela Shenoi received support from the Doris Duke Charitable Foundation (#201516).

189

190

191

192

193

194

195

196

197

198

199

200

201

202

Hospitalization Risk in HIV-COVID19

- 231 [10] Guo, W., H. L. Weng, H. Bai, J. Liu, X. N. Wei, K. Zhou, and A. Sande. 2020. “Quick
232 Community Survey on the Impact of COVID-19 Outbreak for the Health Care of People
233 Living with HIV” [in Chinese]. *Chinese Journal of Epidemiology* 41, no. 5 (May): 662–666.
- 234 [11] Zhu, F., Y. Cao, S. Xu, and M. Zhou. 2020. “Co-infection of SARS-CoV-2 and HIV in a
235 Patient in Wuhan City, China. *Journal of Medical Virology* 92, no. 6 (June): 529–530.
- 236 [12] Docherty, A. B., E. M. Harrison, C. A. Green, H. E. Hardwick, R. Pius, L. Norman, K. A. et
237 al. “Features of 20,133 UK Patients in hospital with COVID-19 Using the ISARIC WHO
238 Clinical Characterisation Protocol: prospective observational cohort study.” 2020. *BMJ*
239 369:m1985. (May) Doi: 110.1136/bmj.m1985.
- 240 [13] Huang, C., Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, et al. 2020. “Clinical Features of
241 Patients Infected with 2019 Novel Coronavirus in Wuhan, China.” *Lancet* 395, no. 10223
242 (February): 497–506.
- 243 [14] Garg, S., L. Kim, M. Whitaker, A. O’Halloran, C. Cummings, R. Holstein, et al. 2020.
244 “Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-
245 Confirmed Coronavirus Disease 2019—COVID-NET, 14 States, March 1–30, 2020.”
246 *Morbidity and Mortality Weekly Report* 69, no. 15 (April): 458–464.
- 247 [15] Gallant, J., P. Y. Hsue, S. Shreay, and N. Meyer. 2017. “Comorbidities among US Patients
248 with Prevalent HIV Infection: A Trend Analysis.” *Journal of Infectious Diseases* 216, no. 12
249 (December): 1525–1533.
- 250 [16] Moran, C. A., N. Oliver, B. V. Szabo, L. F. Collins, M. L. Nguyen, S. Shah, A. et al. 2021.
251 “Comorbidity Burden Is Associated with Hospitalization for COVID-19 among PWH.” Paper
252 presented at the Conference on Retroviruses and Opportunistic Infections (virtual),
253 March 6–10.
- 254 [17] Sun, J., R. Patel, V. Madhira V., A. L. Olex, E. French, J. Y. Islam, R. et al. 2021. “COVID-19
255 Hospitalization among People with HIV or Solid Organ Transplant in the US.” Paper
256 presented at the Conference on Retroviruses and Opportunistic Infections (virtual),
257 March 6–10.
- 258 [18] Zhao, J., X. Liao, H. Wang, L. Wei, M. Xing, L. Liu, and Z. Zhang. 2020. “Early Virus
259 Clearance and Delayed Antibody Response in a Case of Coronavirus Disease 2019 (COVID-
260 19) with a History of Coinfection with Human Immunodeficiency Virus Type 1 and
261 Hepatitis C Virus. *Clinical Infectious Diseases* 71, no. 16 (November): 2233–2235.

Hospitalization Risk in HIV-COVID19

- 262 [19] Yendewa, G. A., J. A. Perez, K. A. Schlick, H. A. Tribout, and G. A. McComsey. 2021.
263 “Characterizing COVID-19 Presentation and Clinical Outcomes in HIV Patients in the US.”
264 Abstract presented at the Conference on Retroviruses and Opportunistic Infections
265 (virtual), March 6–10.
- 266 [20] Del Amo, J., E. Polo, S. Moreno, A. Díaz, E. Martínez, J. R. Arribas, et al. 2021. “Incidence
267 and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy.”
268 *Annals of Internal Medicine* 174, no. 4 (April): 581–582.
- 269 [21] Boulle, A., M-A. Davies, H. Hussey, M. Ismail, E. Morden, Z. Vundle, et al. 2020. “Risk
270 Factors for COVID-19 Death in a Population Cohort Study from the Western Cape
271 Province, South Africa.” *Clinical Infectious Diseases* (Aug). ePub ahead of print version.
272 doi: 10.1093/cid/ciaa1198.
- 273 [22] Webb Hooper, M., A. M. Nápoles, and E. J. Pérez-Stable. 2020. “COVID-19 and
274 Racial/Ethnic Disparities.” *Journal of the American Medical Association* 323, no. 24 (June):
275 2466–2467.
- 276
- 277
- 278
- 279